Miranda Schmalfuhs

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z

Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses key findings from their Global Use of Medicines 2024 report as well as the significant projected growth in spending and growth in diabetes and global obesity

The campaign, that started in 2012, is back with seven new faces—many of which included messaging about the harms of menthol cigarettes.

In this video interview with Pharm Exec Associate Editor Miranda Schmalfuhs, Dr. Jo Varshney, CEO & Founder of VeriSIMLife, discusses how artificial intelligence and machine learning can assist in the drug shortage problem.

Steven Grossman, Co-founder and executive director of the Alliance for a Stronger FDA, discusses the reason for founding the alliance, its members, goals, and the resources they offer.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Matt Jewett, Senior Vice President and General Manager, Diabetes Care US, Roche, discusses where patients are looking for the most support, the correlations between mental health and diabetes, and more.

Sameer Lal, Indegene's Senior Vice President of Enterprise Medical Solutions, discusses their new study 'Reshaping Pharmacovigilance in the Age of AI'

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Five trends in pharmaceutical marketing from the past year.

A discussion of the current standard for diabetes care and how the importance of patient centricity, including addressing patient's mental health, are imperative to the future of the space.

Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.

A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.

A panel at the recent Talk Health event in Philadelphia focused on what success looks like in audio from publisher, vendor, and HCP perspectives.

Injection buys valuable time to formulate care game plans in diabetes management.

In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.

Driving commercial growth and patient access and empowerment in women’s health. (The story of Simon Holland, vice president, women's health commercial lead, for Organon and a 2023 Emerging Pharma Leader.)

How to build a modular content system to optimize content creation and delivery, Using Al-powered engines that know your HCP's viewing behavior, using discomfort as an advantage and much more.

How media consumption is evolving and modifying digital and social strategies to best capture the behavioral changes of HCPs towards digital platforms.

Experts from Karuna Therapeutics discuss current research into schizophrenia as well as psychosis in Alzheimer's disease—including the (lack) of treatment options available for these disorders.

In episode 121, Nathalie Dompé, co-CEO of Dompé Pharmaceuticals, shares a glimpse into her journey in the pharma industry, her leadership style, the differences in working in leadership in the United States vs. Europe (Italy, specifically), and technologies in the biopharma industry.

In episode 120, Nico Saraceno, editor of Pharmaceutical Commerce and host of the Pharmaceutical Commerce Podcast, and Andy Studna, associate editor and cohost of the Applied Clinical Trials Podcast, discuss what their respective podcasts offer to listeners, best guests, and more.

In episode 119, Doina Ionescu, Managing Director, UK & ROI, at Merck, discusses her career journey, gender discrimination in the workplace, her role in the ABPI, and lessons she's taken from Queen Elizabeth II.

In episode 117, Helen Sabzevari, CEO of Precigen, discusses her drive to study science as a Persian-born woman, the opportunities she’s had to research immunology, and how she’s now developing next-generation CAR-T treatments for cancer, in addition to other therapies.

In episode 116, Dr. Greg Rippon, vice president and chief medical partner at Genentech, discusses his work in Alzheimer’s and his outlook for the future of the therapeutic space.

In episode 114, Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses why it’s important to manage high levels of workplace stress, and how companies can help employees in need.

In episode 113, Indranil Bagchi, senior vice president and worldwide head, value and access at Novartis, and member of Pharmaceutical Executive Editorial Advisory Board, discusses the challenges of reaching patients and what he believes can help improve the situation.

In episode 112, Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.

Ken Winell, chief technology officer of Greater Than One, talks about the metaverse and the potential it has to serve the pharma industry.

Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.